Yanchun Meng

851 total citations
41 papers, 655 citations indexed

About

Yanchun Meng is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Yanchun Meng has authored 41 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 16 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Molecular Biology. Recurrent topics in Yanchun Meng's work include HER2/EGFR in Cancer Research (17 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Cancer Treatment and Pharmacology (7 papers). Yanchun Meng is often cited by papers focused on HER2/EGFR in Cancer Research (17 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Cancer Treatment and Pharmacology (7 papers). Yanchun Meng collaborates with scholars based in China, United States and Croatia. Yanchun Meng's co-authors include Bohua Li, Jie Gao, Yajun Guo, Huaiwen Chen, Yu Xia, Weizhu Qian, Yongsheng Yu, Shi Hu, Jianxin Dai and Jinfeng Li and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and Biomaterials.

In The Last Decade

Yanchun Meng

39 papers receiving 644 citations

Peers

Yanchun Meng
Oliver Seifert Germany
Giulia Pellizzari United Kingdom
Khalid Abu Ajaj Germany
Olaf Kinstler United States
Sabine Zitzmann Germany
Majid Lotfinia Iran
Marcelo Fernández Uruguay
Daniel E. Lopes de Menezes Canada
Michelle K. Greene United Kingdom
Oliver Seifert Germany
Yanchun Meng
Citations per year, relative to Yanchun Meng Yanchun Meng (= 1×) peers Oliver Seifert

Countries citing papers authored by Yanchun Meng

Since Specialization
Citations

This map shows the geographic impact of Yanchun Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanchun Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanchun Meng more than expected).

Fields of papers citing papers by Yanchun Meng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanchun Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanchun Meng. The network helps show where Yanchun Meng may publish in the future.

Co-authorship network of co-authors of Yanchun Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Yanchun Meng. A scholar is included among the top collaborators of Yanchun Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanchun Meng. Yanchun Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Jiong, Jian Zhang, Man Li, et al.. (2024). A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1047–1047. 1 indexed citations
2.
Meng, Yanchun, Xiaojun Liu, Yuxin Mu, et al.. (2024). Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.. Journal of Clinical Oncology. 42(16_suppl). e14600–e14600. 1 indexed citations
3.
Zhang, Jian, Yiqun Du, Yanchun Meng, et al.. (2024). First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors. npj Precision Oncology. 8(1). 200–200. 2 indexed citations
4.
Zhang, Jian, Rujiao Liu, Shuiping Gao, et al.. (2023). Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours. npj Breast Cancer. 9(1). 28–28. 36 indexed citations
5.
Tang, Qiqi, Beibei Liang, Lisha Zhang, et al.. (2022). Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation. Scientific Reports. 12(1). 17350–17350. 25 indexed citations
6.
Zhang, Jian, Yanchun Meng, Biyun Wang, et al.. (2022). Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. Frontiers in Oncology. 12. 775081–775081. 11 indexed citations
7.
Meng, Yanchun, Hao Tang, Zhiguo Luo, et al.. (2021). An integrated bioinformatics analysis to investigate the targets of miR-133a-1 in breast cancer. Translational Cancer Research. 10(3). 1238–1248. 2 indexed citations
8.
Zhang, Xiaowei, Feng Jin, Shiyu Jiang, et al.. (2021). Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data. Investigational New Drugs. 40(2). 453–460. 7 indexed citations
9.
Meng, Yanchun, Juan Jin, Chengcheng Gong, et al.. (2021). Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer. Annals of Palliative Medicine. 10(11). 11255–11264. 18 indexed citations
10.
Meng, Yanchun, et al.. (2020). The function of SOX2 in breast cancer and relevant signaling pathway. Pathology - Research and Practice. 216(8). 153023–153023. 13 indexed citations
11.
Li, Zhaoliang, Yanchun Meng, Shengtao Xu, et al.. (2017). Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. Bioorganic & Medicinal Chemistry. 25(10). 2772–2781. 19 indexed citations
12.
Yu, Xiaojie, Lingfei Wang, Yafeng Shen, et al.. (2017). Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody. Molecular Immunology. 87. 300–307. 19 indexed citations
13.
Shi, Xin, Yong‐Qiang Deng, Huajing Wang, et al.. (2016). A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion. mAbs. 8(3). 574–584. 24 indexed citations
14.
Wang, Lingfei, Xiaojie Yu, Jian Dong, et al.. (2016). Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer. Biochemical and Biophysical Research Communications. 479(3). 563–570. 5 indexed citations
15.
Zhang, Yajun, Lingfei Wang, Xiaodan Chong, et al.. (2016). A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth. Biochemical and Biophysical Research Communications. 477(4). 755–760. 3 indexed citations
16.
Chen, Yalin, Lin Chen, Qiong Lu, et al.. (2015). Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis. Biochemical and Biophysical Research Communications. 459(4). 617–622. 3 indexed citations
17.
Li, Bohua, Yanchun Meng, Lei Zheng, et al.. (2013). Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization. Cancer Research. 73(21). 6471–6483. 47 indexed citations
18.
19.
Li, Wei, Jinfeng Li, Jie Gao, et al.. (2011). The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials. 32(15). 3832–3844. 110 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliver Seifert Breakdown of academic impact, for papers by Giulia Pellizzari Breakdown of academic impact, for papers by Khalid Abu Ajaj Breakdown of academic impact, for papers by Olaf Kinstler Breakdown of academic impact, for papers by Sabine Zitzmann Breakdown of academic impact, for papers by Majid Lotfinia Breakdown of academic impact, for papers by Marcelo Fernández Breakdown of academic impact, for papers by Daniel E. Lopes de Menezes Breakdown of academic impact, for papers by Michelle K. Greene
Rankless by CCL
2026